Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary "Taiwan Meiji Pharma Co...

Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary "Taiwan Meiji Pharma Co., Ltd." in Taiwan  Business Wire

Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production - StockTitan

Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production  StockTitan

Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovati...

Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies  Yahoo Finance

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Sel...

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma  PR Newswire

Meiji Seika Pharma to supply Japan with self-amplifying mRNA Covid-19 vaccine in fall/winter of 2...

Meiji Seika Pharma to supply Japan with self-amplifying mRNA Covid-19 vaccine in fall/winter of 2024  Endpoints News

Meiji Seika Pharma invests in ARCALIS to boost production of mRNA vaccines in Japan - BSA bureau

Meiji Seika Pharma invests in ARCALIS to boost production of mRNA vaccines in Japan  BSA bureau

Japan pharma mulls suing lawmaker who likened new COVID vaccine to 'biological weapon' - The Main...

Japan pharma mulls suing lawmaker who likened new COVID vaccine to 'biological weapon'  The Mainichi

Meiji Seika Pharma commences Phase III mRNA Covid-19 vaccine trial in Japan - Clinical Trials Arena

Meiji Seika Pharma commences Phase III mRNA Covid-19 vaccine trial in Japan  Clinical Trials Arena

CSL, Arcturus get first approval for self-assembling RNA jab - pharmaphorum

CSL, Arcturus get first approval for self-assembling RNA jab  pharmaphorum

Arcturus JV scored $115M in Japanese grants to boost mRNA manufacturing - FiercePharma

Arcturus JV scored $115M in Japanese grants to boost mRNA manufacturing  FiercePharma

Japan's Meiji Seika to build $20.1M manufacturing plant in India - FiercePharma

Japan's Meiji Seika to build $20.1M manufacturing plant in India  FiercePharma

Meiji Seika Pharma: Adcock Ingram Pharma Private Limited Completes Construction of a New Manufact...

Meiji Seika Pharma: Adcock Ingram Pharma Private Limited Completes Construction of a New Manufacturing Facility in India to Enhance its CMO Business  Business Wire

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent ...

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023  Business Wire

Meiji Seika Pharma Sets up a New Subsidiary in the US - Business Wire

Meiji Seika Pharma Sets up a New Subsidiary in the US  Business Wire

Meiji Seika Pharma Co., Ltd: Support for Control of Novel Coronavirus in China - Business Wire

Meiji Seika Pharma Co., Ltd: Support for Control of Novel Coronavirus in China  Business Wire

Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility - Co...

Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility  Contract Pharma

Meiji Seika Pharma to Launch Two Products from Santen Pharmaceutical Co., Ltd. in Indonesia - Bus...

Meiji Seika Pharma to Launch Two Products from Santen Pharmaceutical Co., Ltd. in Indonesia  Business Wire

AstraZeneca taps JCR Pharmaceuticals, Daiichi Sankyo and other local pharmas to supply COVID-19 s...

AstraZeneca taps JCR Pharmaceuticals, Daiichi Sankyo and other local pharmas to supply COVID-19 shots to Japan  FiercePharma

Mitsui Chemicals to buy Meiji Seika agro business - Speciality Chemicals Magazine

Mitsui Chemicals to buy Meiji Seika agro business  Speciality Chemicals Magazine

Japan's Meiji Seika Pharma expands CMO business in India - BSA bureau

Japan's Meiji Seika Pharma expands CMO business in India  BSA bureau

A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint researc...

A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe  NTB Kommunikasjon

Dong-A ST and Meiji Seika sign ustekinumab deal with Intas - The Korea JoongAng Daily

Dong-A ST and Meiji Seika sign ustekinumab deal with Intas  The Korea JoongAng Daily

Japan to produce 90m doses of AstraZeneca COVID-19 vaccine - Nikkei Asia

Japan to produce 90m doses of AstraZeneca COVID-19 vaccine  Nikkei Asia